shionogi

Press Release Backnumber

Adobe Reader To view these files you must have the Adobe Reader installed on your system. Adobe Reader is availabe for free from the Adobe website. To download and install the software please click on the button.

2010

2010/12/27 Shionogi to enter into licensing agreement on NF-kappaB Decoy Oligodeoxynucleotide for Atopic Dermatitis with AnGes MG, Inc.
2010/12/06 Shionogi has entered into a licensing agreement on peptide vaccines for ophthalmic disease with OncoTherapy Science, Inc.
2010/11/01 Shionogi to make its subsidiary into a wholly owned subsidiary, and to change the corporate name
2010/10/28 Shionogi and GlaxoSmithKline to collaborate on the research, development and commercialization of novel antibiotics targeting drug-resistant Gram-negative bacteria
2010/10/27 Shionogi Receives an Approval foran Additional Indication for Pediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza
2010/10/22 Notice of Revisions of Earnings Forecasts
2010/10/21 Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
2010/10/20 Shionogi reached an agreement to settle patent-infringement lawsuit for Flomox® (Oral cephem antibiotic agent)
2010/10/15 Shionogi Signs Agreement with Sweden on International Industry-Academic Collaboration Initiatives
2010/09/28 Establishment of an Organization and Personnel Reassignment
2010/09/07 License agreements with Stallergenes regarding sublingual allergen immunotherapy tablets
2010/09/01 Dissolution of a Subsidiary
2010/08/02 Financial Results for the First Quarter of Fiscal Year 2010
2010/07/23 Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference
2010/07/21 Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor
2010/07/01 Shionogi announces reorganization of US Operations, new leadership.
2010/06/30 CRESTOR® PATENT UPHELD BY US DISTRICT COURT, DISTRICT OF DELAWARE
2010/06/17 Establishment of an Organization
2010/06/01 Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type-
2010/05/10 Shionogi Establishes Shionogi Techno Advance Research Co., Ltd.
2010/05/10 New Quinolone Oral Antibiotic Avelox®: Sales Rights Transfer
2010/04/27 Shionogi Appeals Patent Infringement lawsuit for Flomox® (Oral cephem antibiotic agent) to the Intellectual Property High Court
2010/04/16 Launch of an Antidepressant Drug,"Cymbalta® Capsules 20mg and 30mg"
2010/03/16 SHIONOGI'S THIRD MEDIUM-TERM BUSINESS PLAN
2010/03/11 Shionogi and TAKATA SEIYAKU Announce Agreement on Succession of Marketing and Manufacturing Rights
2010/03/02 SHIONOGI ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH QUATRX PHARMACEUTICALS TO MARKET OSPEMIFENE
2010/02/22 NOTIFICATION OF SUBSIDIARY TRANSFER
2010/02/22 Shionogi Announces Appointment of Directors, Corporate Officers and Corporate Reorganization
2010/02/15 Shionogi Files an Additional Application for Pediatric Use of "RAPIACTA®" a Novel Anti-viral Drug for Influenza
2010/02/01 Financial Results for the Third Quarter of Fiscal Year 2009
2010/01/26 A Novel Anti-viral Drug for Influenza,"RAPIACTA 300mg Bag for Intravenous Drip Infusion" and "RAPIACTA 150mg Vial for Intravenous Drip Infusion" Launch
2010/01/25 Shionogi Supports Relief Efforts for Haiti Earthquake Victims
2010/01/20 Shionogi Receives Marketing and Manufacturing Approval of an Antidepressant Drug,"Cymbalta ®Capsules 20mg and 30mg"
2010/01/13 Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, "RAPIACTA 300mg Bag for Intravenous Drip Infusion" and "RAPIACTA 150mg Vial for Intravenous Drip Infusion"
2010/01/12 SCIELE PHARMA, INC., A SHIONOGI GROUP COMPANY, ANNOUNCES NAME CHANGE

2009

2009/11/16 SCIELE PHARMA, A SHIONOGI COMPANY, TO ACQUIRE ADDRENEX PHARMACEUTICALS, INC., A U.S. SPECIALTY PHARMACEUTICAL COMPANY
2009/11/04 Shionogi Filed a New Drug Application for Peramivir, a Novel Anti-viral Drug for Influenza
2009/10/30 Shionogi Announces the 2009 Results of Drug Discovery Competition
2009/10/09 Shionogi Signs Agreement with United Kingdom on International Industry-Academic Collaboration Initiatives
2009/09/15 Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects
2009/09/14 Cancer Pain Analgesic Additional Volume of OxiNorm® Powder 0.5% 2g (10mg/pouch)
2009/08/19 Personnel Reassignments
2009/08/18 Shionogi Files a Patent Infringement Action against a Generic Company for Flomox® (Oral cephem antibiotic agent)
2009/08/03 Shionogi Announces the Reduction of the Minimum Investment Unit and an Amendment to its Articles of Incorporation
2009/07/29 Personnel Reassignments
2009/07/21 Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
2009/07/17 Shionogi announces positive results from Phase3 studies of peramivir, a novel anti-viral drug for influenza
2009/07/10 SCIELE PHARMA, A SHIONOGI COMPANY, TERMINATES AGREEMENT TO ACQUIRE VICTORY PHARMA, INC.
2009/06/04 Notification with Respect to Issuance of Unsecured Straight Bonds
2009/06/01 Shionogi Announces the Conducting of Drug Discovery Competition"FINDS" in 2009
2009/05/18 SCIELE PHARMA, A SHIONOGI COMPANY, TO ACQUIRE VICTORY PHARMA, INC., A U.S. SPECIALTY PHARMACEUTICAL COMPANY
2009/05/15 Fluitran® 1mg Tablets Launches
2009/05/11 Shionogi Announces an Amendment to its Articles of Incorporation
2009/05/11 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2009/03/30 Establishment of an Organization and Personnel Reassignments
2009/03/16 Shionogi establishes "Medicinal Molecular Imaging Center (Tentative)" in order to promote joint research with Osaka University Graduate School of Medicine and Faculty of Medicine
2009/03/16 Shionogi Announces Introduction of External Board Members Appointment of Directors and Corporate Officers
2009/02/23 Shionogi establishes Ezose Sciences, a jointly-owned US venture company providing serum glycan analysis services
2009/02/19 Shionogi Files Patent Infringement Actions against a Bulk Powder Import Company and Files Suspension of Import with Customs for Flomox®(Oral cephem antibiotic agent)
2009/02/17 Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
2009/02/02 Shionogi announces it has entered into a licensing agreement on Peptide vaccines for cancer treatment with OncoTherapy Science, Inc.
2009/02/02 Corporate Reorganization and Personnel Reassignments
2009/02/02 Notice of Revision of Earnings Forecast for the Year Ending March 31, 2009

2008

2008/12/12 Pirespa® 200mg Tablet Launched Idiopathic Pulmonary Fibrosis Treatment
2008/11/26 Additional Adult Indication Approved for Flomox® Fine Granules 100mg for children Oral cephem antibiotic agent
2008/11/11 Shionogi Announces Completion of Construction of a New Facility for Formulation and Packaging of Solid Dosage Forms at the Settsu Plant
2008/10/31 Shionogi Announces the 2008 Results of Drug Discovery Competition
2008/10/16 Shionogi Receives Marketing and Manufacturing Approval for Pirespa® 200mg Tablets Idiopathic Pulmonary Fibrosis Treatment
2008/10/14 A novel topical treatment for acne vulgaris Differin® Gel 0.1% Launches
2008/10/10 Shionogi and Siele Announce Completion of Subsequent Offering Period
2008/10/10 Shionogi Completes Acquisition of Sciele
2008/10/06 Shionogi and Sciele Announce successful tender offer and commencement of subsequent offering
2008/09/19 Shionogi and Sciele Announce Receipt of United States Antitrust Clearance
2008/09/01 Acquisition of Sciele Pharma, Inc.
2008/09/01 Shionogi & Co., Ltd. Acquires US-based Sciele Pharma, Inc.
2008/07/16 Marketing and Manufacturing Approval for Differin® Gel 0.1%
2008/06/23 Angiotensin II Receptor Blockers (ARBs) for treatment of Hypertension Irbetan® 50mg and 100mg Tablets Launches
2008/05/30 Shionogi Establishes Joint Research Facility, "Shionogi Innovation Center for Drug Discovery"with Hokkaido University
2008/05/12 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2008/04/23 Shionogi Announces the Conducting of Drug Discovery Competition "FINDS" in 2008
2008/04/21 Notice of Revision of Dividend Forecast for Year Ended March 31, 2008
2008/04/17 Shionogi Receives Marketing and Manufacturing Approval for Irbetan® 50mg and 100mg Tablets
2008/03/17 Changes of Representative Directors and Corporate Officers
2008/02/27 Corporate Reorganization and Personnel Reassignments
2008/01/28 Construction of New Research Facility
2008/01/21 Claritin® Dry Syrup 1% Launched

2007

2007/12/12 Shionogi Files Patent Infringement Actions in Response to Crestor® ANDAs in the USA
2007/11/08 Notice of Execution and Completion of Acquisition of the Company's Own Shares
2007/10/31 Shionogi Announces the 2007 Results of Drug Discovery Competition FINDS
2007/10/19 Additional Pediatric Indication Approved for Claritin®
2007/10/19 Approval received for Claritin® Dry Syrup 1%
2007/10/16 Notice of Execution of Acquisition of the Company's Own Shares
2007/10/02 Establishment of Shionogi Analysis Center Co., Ltd.
2007/09/18 Notice of Acquisition of the Company's own shares
2007/05/14 Shionogi Announces an Amendment to Its Articles of Incorporatiojn
2007/05/14 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2007/04/20 PRIME Program"Report of Results of CRESTOR® Clinical Experience Investigation (CEI) study of Approximately 10,000 Japanese Patients"
2007/04/16 Shionogi Announces the Opening of Drug Discovery Competition FINDS
2007/04/04 Shionogi Announces Revisions to the Second Medium-Term Business Plan
2007/04/04 Notice of Revision of Results Forecast for the Year Ended March 31, 2007
2007/03/26 Shionogi Announces Organizational and Personnel Changes
2007/03/06 Shionogi Concludes License Agreement with BioCryst Pharmaceuticals for Anti-Influenza Drug Peramivir
2007/02/26 Shionogi Announces Organizational and Personnel Changes
2007/02/05 Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5%
2007/02/02 Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine in Japan

2006

2006/12/22 Results of Phase III Clinical Trials of the Idiopathic Pulmonary Fibrosis Treatment S-7701
2006/10/27 Shionogi Discontinues Development of S-5751, a Prostaglandin D2 Receptor Antagonist
2006/10/20 Shionogi Obtained Manufacturing and Marketing Approval for Cancer Pain Analgesic OXINORM powder 0.5%
2006/10/19 Announcement of Final Results of JATOS, Japanfs First Large-Scale Clinical Trial for Treatment of Hypertension in Elderly Patients
2006/10/05 Basic Agreement Reached on Construction of Joint Research Facility
2006/09/21 Launch of Premature Ovulation Inhibitor Cetrotide®0.25mg and 3mg for Injection (Cetrorelix Acetate)
2006/08/15 GLAXOSMITHKLINE AND SHIONOGI COMPLETE INITIAL CLINICAL STUDY FOR HIV INTEGRASE INHIBITOR
2006/08/07 The analysis from the interim report of post-marketing surveillance for Crestor® submitted to the regulatory authority
2006/07/10 Shionogi announces positive results from a Phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of Obesity
2006/07/07 Shionogi to Launch Non-pyrazolone Antipyretic Analgesic “Sedes®V“
2006/06/09 Shionogi Launches Carbapenem Antibiotic Product “Finibax®0.25g IV Solution Kit”
2006/05/16 Marketing Agreement for Rapid BNP Test “SHIONOSPOT® BNP” and the Associated Measurement System “SHIONOSPOT® Reader”
2006/04/24 Notice of Revision of Dividend Forecast for Year Ended March 31,2006
2006/04/20 Manufacturing and Marketing Approval for Premature Ovulation Inhibitor Cetrotide®(Cetrorelix Acetate) Obtained
2006/03/07 Shionogi and Galderma Announce Memorandum of Understanding Regarding Adapalene gel 0.1%, a topical treatment of acne vulgaris
2006/01/10 Shionogi and Purdue Pharma L.P. Sign Multi-Year Research and Worldwide Co-Marketing Agreement for Novel Analgesic Drug Compounds

2005

2005/12/09 Launch of Avelox® Tablet, the new quinolone antibacterial (Moxifloxacin)
2005/11/07 Application to Delist Shares (Nagoya/Sapporo/Fukuoka)
2005/10/11 Bayer Yakuhin Ltd. granted the importing rights for Avelox® Tablet, the new quinolone antibacterial (Moxifloxacin)
Shionogi & Co. Ltd. have exclusive Japanese marketing rights
2005/09/16 Launch of Carbapenem Antibiotic "Finibax® 0.25g IV Solution"
2005/07/25 Shionogi Receives Approval to Manufacture and Market Carbapenem Antibiotic "Finibax® 0.25g IV Solution"
2005/06/16 Launch of "Sedes® cure"
2005/04/27 Hypercholesterolaemia treatment drug "CRESTOR®" Launched
2005/04/25 The Second Medium-Term Management Plan
2005/03/23 Notice of Repurchase of Shares
2005/03/14 Notice of Revision of Dividend Forecast for Year Ending March 31, 2005
2005/01/31 Notice of Repurchase of Shares
2005/01/19 Hypercholesterolaemia treatment drug"CRESTOR®" Approved

2004

2004/12/27 rosuvastatin calcium
2004/11/30 Launch Announcement of "Popon-C white"
2004/11/22 Position Regarding Media Reports on November 18
2004/11/12 Launch Announcement of "CLARITIN® RediTabs® ,10mg Tablet"
2004/08/30 Distribution and Marketing of CEDAX ® (ceftibuten) in the United States
2004/07/28 License agreement between Enanta and Shionogi
2004/04/19 Notice of Revision of FY 2003 Results Forecast
2004/04/19 Introduction of New Retirement Benefit System
2004/03/22 Announcement of Management Structure Reforms and Executive and Organizational Changes

2003

2003/12/08 Basic Agreement on Transfer of Manufacturing Operations for Agrochemical and Animal Health Products
2003/10/22 Shionogi begins a novel glycoprotein research effort with Hokkaido University
2003/10/20 Notice of Rivision of FY 2003 Results Forecast
2003/10/17 Bayer Yakuhin, Ltd. and Shionogi & Co., Ltd. Form Alliance to Distribute Moxifloxacin in Japan
2003/09/26 DSL.Japan Co.,Ltd.,a Joint Venture for Precipitated Silica, Silica Gel and Matting Agents,Begins Business
2003/07/24 Announcement of Change of Launch Schedule for New Treatment for Hyperlipidemia Rosuvastatin Calcium
2003/07/07 Launch Announcement of Controlled-Released Oral Analgesic for Cancer Pain
2003/07/07 Notice of Closing of Sapporo Distribution Center
2003/06/24 Degussa and Shionogi establish Precipitated Silica/Silica Gel/Matting Agents Joint Venture in Japan
2003/05/26 Licensing Agreement with Peninsula Pharmaceuticals, Inc.of the U.S.
2003/05/19 Notice of Outplacement Support Program and Other Matters
2003/05/19 Acquistion of Treasury Stock
2003/03/03 GlaxoSmithKline and Shionogi to co-promote the anti-viral agents
2003/01/27 Shionogi to Merge Six Subsidiaries by Absorption

2002

2002/11/11 Results of the Outplacement Support Program in the Manufacturing Division
2002/10/25 Notice of Implementation of Business Structure Reengineering Measures and Revision of FY 2002 Results Forecast
2002/10/17 Notice of the Conclusion of the Agreement on the BNP Test Reagent
2002/08/30 Announcement on launch on anti-allergic product "Claritin® 10mg"
2002/08/27 Notice of Additional Clinical Trials for Anti-Depressant "Duloxetine"
2002/08/06 Announcement of business collaboration on human genome-based drug research
2002/07/10 Results of First Human Trial of a New Class of Anti-HIV Drugs Reported by Shionogi-GSK
2002/07/08 Announcement on an approval on anti-allergic product
2002/05/20 Acquisition of Treasury Stock
2002/05/20 Merger Agreement Signed by Our Subsidiary
2002/05/20 Outplacement/Retirement Plan Introduced by Ohmori
2002/05/16 AstraZeneca and Shionogi to Co-market Rosuvastatin Calcium, a New Treatment for Dyslipidaemia
2002/04/01 Clinical Testing Service Joint Venture Commences Operations
2002/04/01 Boehringer Ingelheim Shionogi Vetmedica Commences Operations
2002/03/26 7 Branches and 3 Consolidated Subsidiaries Accredited to ISO14001

2001

2001/11/20 Basic Agreement Reached on Joint Venture for Clinical Testing Service
2001/10/23 Final Agreement Reached on GSK-Shionogi Joint Venture Project
2001/10/16 Boehringer Ingelheim and Shionogi to form Joint Venture in The Animal Health Business
2001/09/25 Establishment of Aventis CropScience Shionogi K.K.
2001/07/24 GSK and Shionogi to enter global multi-product development and commercialization alliance
2001/07/11 Announcement of business partnership agreement signing by our subsidiary
2001/05/31 Future Agrochemical Business
2001/05/14 Establishment of 'Shionogi USA, Inc.'
2001/05/14 Reorganization of Sales Structure for Non-cropland Market
2001/03/28 Introduction of Invention Compensation System
2001/01/22 Co-promotion deal on Anti-A and B type influenza agent developped by Nippon Roche
2001/01/19 Co-marketing of an anti-allergy product

2000

2000/01/26 Announcement of the Signing of a Collaborative Research Agreement with the American company Quark Biotech,inc.(QBI)

1998

1998/08/10 Establishment of the Manufacturing Subsidiary
1998/06/29 Licensing out of an Anti-HIV compound to Agouron Pharmaceuticals, Inc.
1998/05/07 Merger of 11 Subsidiary Wholesalers

1997

1997/07/02 Foundation of Shionogi BioResearch Corp. (SBR) - US Subsidiary aimed at the discovery of new drugs

page top